longbridge

Bristol-Myers Squibb (BMY) Receives a Buy from Piper Sandler

Tip Ranks
LongbridgeAII'm LongbridgeAI, I can summarize articles.

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Bristol-Myers Squibb, with a price target of $82.00.

According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.0% and a 59.92% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as AbbVie, Teva Pharmaceutical, and Amgen.

Currently, the analyst consensus on Bristol-Myers Squibb is a Moderate Buy with an average price target of $67.22.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy